SHARE

Latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis B – Pipeline Review, H1 2018, provides an overview of the Hepatitis B pipeline landscape.

Pharmaceutical and Healthcare latest pipeline guide Hepatitis B – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hepatitis B , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis B pipeline guide also reviews of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are:- 3, 2, 9, 26, 24, 1, 69, 29 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 1, 9 and 3 molecules, respectively.

Hepatitis B pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Companies Mentioned in Hepatitis B are: Abivax SA, AiCuris GmbH & Co KG, AIMM Therapeutics BV, Akshaya Bio Inc, Alnylam Pharmaceuticals Inc, Altimmune Inc, Altravax Inc, Amarna Therapeutics BV, Arbutus Biopharma Corp, Arcturus Therapeutics Ltd, Arrowhead Pharmaceuticals Inc, Ascentage Pharma Group Corp Ltd, Assembly Biosciences Inc, Aucta Pharmaceuticals LLC, Beijing Kawin Technology Share-Holding Co Ltd, Beijing Minhai Biotechnology Co Ltd, Benitec Biopharma Ltd, Biological E Ltd, BioStar Pharmaceuticals Inc, Biotron Ltd, Bolder Biotechnology Inc, BrightGene Bio-Medical Technology Co Ltd, Bukwang Pharm Co Ltd, Cadila Healthcare Ltd, CaroGen Corp, Celltrion Inc, Chong Kun Dang Pharmaceutical Corp, Chongqing Zhifei Biological Products Co Ltd, Chromis Therapeutics Inc, Cocrystal Pharma Inc, ContraVir Pharmaceuticals Inc,  CyTuVax BV, DelSiTech Ltd, Dicerna Pharmaceuticals Inc, Dong-A Socio Holdings Co Ltd, Ensemble Therapeutics Corp, Enyo Pharma SA, Excision BioTherapeutics Inc, F. Hoffmann-La Roche Ltd, GC Pharma, GeneCure LLC, GeoVax Labs Inc, Gilead Sciences Inc, GlaxoSmithKline Plc, Huons Global Co Ltd, Immunotope Inc,  Indian Immunologicals Ltd, Inovio Pharmaceuticals Inc, Intellia Therapeutics Inc, Ionis Pharmaceuticals Inc, ISA Pharmaceuticals BV, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Johnson & Johnson, Kainos Medicine Inc, Kineta Inc, LG Chem Ltd, Microbiotix Inc, MultiCell Technologies Inc, Oncolys BioPharma Inc, Pfenex Inc, PharmaEssentia Corp, Profarma, Profectus BioSciences Inc, Qilu Pharmaceutical Co Ltd, Replicor Inc, Rodos BioTarget GmbH, Samjin Pharm Co Ltd, Sanofi Pasteur SA, Scynexis Inc, Shantha Biotechnics Pvt Ltd, Sino Biopharmaceutical Ltd, Spring Bank Pharmaceuticals Inc, TCM Biotech International Corp, Theravectys SA, THEVAX Genetics Vaccine USA Inc, Transgene SA, Vaccitech Ltd, Vaxine Pty Ltd, VBI Vaccines Inc, Vical Inc, ViroStatics srl, VLP Biotech Inc.

Request for a Sample Copy of this Research Report at: https://www.marketinsightsreports.com/reports/0926875065/hepatitis-b-pipeline-review-h1-2018/inquiry?source=apexnews&Mode=01

Scope:

  1. The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis B.
    2. The pipeline guide reviews pipeline therapeutics for Hepatitis B by companies and universities/research institutes based on information derived from company and industry-specific sources.
    3. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    4. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    5. The pipeline guide reviews key companies involved in Hepatitis B therapeutics and enlists all their major and minor projects.
    6. The pipeline guide evaluates Hepatitis B therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    7. The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    8. The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis B

Browse full Report at: https://www.marketinsightsreports.com/reports/0926875065/hepatitis-b-pipeline-review-h1-2018?source=apexnews&Mode=01

Reasons to buy this Report:

1. procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
2. Find and recognize significant and varied types of therapeutics under development for Hepatitis B.
Classify potential new clients or partners in the target demographic.
3. Develop tactical initiatives by understanding the focus areas of leading companies.
4. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
5. Formulate corrective measures for pipeline projects by understanding Hepatitis B pipeline depth and focus of Indication therapeutics.
6. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
7. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Important Points Covered In Table of Content are:

Therapeutics Assessment, Assessment by Target, Assessment by Mechanism of Action, Assessment by Route of Administration, Assessment by Molecule Type, Pipeline Overview, Pipeline by Companies, Pipeline by Universities/Institutes, Products under Development by Companies, Products under Development by Universities/Institutes.